Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 12:11:627270.
doi: 10.3389/fonc.2021.627270. eCollection 2021.

Visceral Obesity, Metabolic Syndrome, and Esophageal Adenocarcinoma

Jessie A Elliott  1 , John V Reynolds  1
Affiliations
Review

Visceral Obesity, Metabolic Syndrome, and Esophageal Adenocarcinoma

Jessie A Elliott et al. Front Oncol. .

Abstract

Esophageal adenocarcinoma (EAC) represents an exemplar of obesity-associated carcinogenesis, with a progressive increase in EAC risk with increased body mass index. In this context, there is increased focus on visceral adipose tissue and associated metabolic dysfunction, including hypertension, diabetes mellitus and hyperlipidemia, or combinations of these in the metabolic syndrome. Visceral obesity (VO) may promote EAC via both directly impacting on gastro-esophageal reflux disease and Barrett's esophagus, as well as via reflux-independent effects, involving adipokines, growth factors, insulin resistance, and the microbiome. In this review these pathways are explored, including the impact of VO on the tumor microenvironment, and on cancer outcomes. The current evidence-based literature regarding the role of dietary, lifestyle, pharmacologic and surgical interventions to modulate the risk of EAC is explored.

Keywords: Barrett's esophagus; adenocarcinoma; esophageal cancer; gastroesophageal reflux; metabolic syndrome; obesity; tumor microenvironment; visceral obesity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Mechanisms linking visceral obesity and esophageal adenocarcinoma.
See this image and copyright information in PMC

References

    1. Then EO, Lopez M, Saleem S, Gayam V, Sunkara T, Culliford A, et al. Esophageal cancer: an updated surveillance epidemiology and end results database analysis. World J Oncol. (2020) 11:55–64. 10.14740/wjon1254 - DOI - PMC - PubMed
    1. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants . Lancet. (2016) 387:1377–96. 10.1016/S0140-6736(16)30054-X - DOI - PMC - PubMed
    1. Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. (2015) 16:1090–8. 10.1016/S1470-2045(15)00040-6 - DOI - PubMed
    1. Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TM, Myklebust T, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. (2019) 20:1493–505. 10.1016/S1470-2045(19)30456-5 - DOI - PMC - PubMed
    1. Reynolds JV, Donohoe CL, McGillycuddy E, Ravi N, O'Toole D, O'Byrne K, et al. Evolving progress in oncologic and operative outcomes for esophageal and junctional cancer: lessons from the experience of a high-volume center. J Thorac Cardiovasc Surg. (2012) 143:1130–7.e1. 10.1016/j.jtcvs.2011.12.003 - DOI - PubMed

LinkOut - more resources